GlassScriptPhysician profile
Maria M Jirka
NPI 1093895633
$3,772.61
in general payments reported to CMS, 2019-2025
18 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $334 · 2021: $301 · 2022: $407 · 2023: $1,614 · 2024: $306 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $847.75 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $654.98 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $560.29 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $425.41 | 2021-2025 | |
| Lilly USA, LLC | $401.81 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $322.45 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $140.27 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $105.12 | 2022 | |
| Exact Sciences Corporation | $90.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $81.22 | 2019-2024 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $30.66 | 2023-2025 | Contrave |
| Amgen INC. | $20.21 | 2023 | Otezla, Repatha |
| Si-Bone, INC. | $20.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.12 | 2022 | |
| Esperion Therapeutics, INC. | $15.72 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.81 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $12.87 | 2023 | Quviviq |
| Pfizer INC. | $12.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Jirka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.